In conclusion, we observed no obvious difference in the extend of radiosensitization between the EGFRvIII− and EGFRvIII+ cell lines, therefore demonstrating that Wee1 inhibition can effectively radiosensitize both EGFRvIII− and EGFRvIII+ GBM cells and could therefore be an efficient new treatment option also for tumors displaying heterogeneous EGFRvIII expression. Here, WEE1 is linked to glioblastoma.